Technology is revolutionising medicine, and telemedicine is having a measurable impact on stroke care
Technology is revolutionising medicine, and telemedicine for patients with stroke (telestroke) is now having a measurable impact on outcomes. Acute stroke care is challenging for many reasons: stroke mimics are common (about 30% of all cases initially suspected to be stroke);1 patients with intracerebral haemorrhage and ischaemic stroke can present with identical syndromes, making brain imaging essential for diagnosis; treatments must be initiated without delay, and some require transfer for tertiary intervention (eg, endovascular thrombectomy). The lack of specialist stroke physicians in regional Australia and underinvestment in stroke care results in poor access for many Australians. Unwarranted clinical variation is unacceptable, so why do some regions of Australia, even today, have no access to specialist stroke care? The answers are complex, but some are clear (too few specialists in regional areas), while some are more difficult to understand (health providers declining offers of help).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Bladin C, Kim J, Bagot KL, et al. Improving acute stroke care in regional hospitals: clinical evaluation of the Victorian Stroke Telemedicine program. Med J Aust 2020; 212: 371–376.
- 2. National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587.
- 3. Stroke Foundation. Stroke symptoms. Undated. https://strokefoundation.org.au/About-Stroke/Stroke-symptoms (viewed Mar 2020).
- 4. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta‐analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–1935.
- 5. Saver JL. Time is brain‐quantified. Stroke 2006; 37: 263–266.
- 6. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013; 309: 2480–2488.
- 7. Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2013; CD000197.
- 8. Wang Y, Johnston SC, Bath PM, et al. BMJ 2019; 364: l895.
- 9. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large‐vessel ischaemic stroke: a meta‐analysis of individual patient data from five randomised trials. Lancet 2016; 387: 1723–1731.
- 10. Parry‐Jones AR, Sammut‐Powell C, Paroutoglou K, et al. An intracerebral hemorrhage care bundle is associated with lower case fatality. Ann Neurol 2019; 86: 495–503.
- 11. Anderson CS, Heeley E, Huang Y, et al. Rapid blood‐pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355–2365.
- 12. Reed SD, Cramer SC, Blough DK, et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001; 32: 1832–1840.
I am supported by a National Health and Medical Research Council program grant (APP1149987: Clinical, public health and policy interventions to combat cardiovascular diseases).
No relevant disclosures.